|
FBXO4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.66133814775094E-16 |
| Normal-vs-Stage2 |
5.68130000044853E-07 |
| Normal-vs-Stage3 |
9.1630036891388E-12 |
| Normal-vs-Stage4 |
1.14579457033415E-11 |
| Stage1-vs-Stage2 |
8.140800E-01 |
| Stage1-vs-Stage3 |
8.990000E-01 |
| Stage1-vs-Stage4 |
3.283400E-01 |
| Stage2-vs-Stage3 |
7.555200E-01 |
| Stage2-vs-Stage4 |
4.445000E-01 |
| Stage3-vs-Stage4 |
4.812600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
9.71290000000291E-05 |
| Normal-vs-Asian |
1.1526002374751E-10 |
| Caucasian-vs-AfricanAmerican |
4.065200E-01 |
| Caucasian-vs-Asian |
9.002600E-01 |
| AfricanAmerican-vs-Asian |
4.838400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.15000026063217E-10 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
1.161840E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.77535763867809E-12 |
| Normal-vs-Age(41-60Yrs) |
1.37445610448594E-13 |
| Normal-vs-Age(61-80Yrs) |
2.6612045900265E-12 |
| Normal-vs-Age(81-100Yrs) |
1.341570E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.939200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.286200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.522200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.708600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.009800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.436000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.454500E-02 |
| Classical-VS-Follicular |
4.279800E-01 |
| Classical-VS-Other |
9.153600E-01 |
| Classical-VS-Normal |
3.71270014731806E-10 |
| Tall-VS-Follicular |
3.809600E-01 |
| Tall-VS-Other |
5.290600E-01 |
| Tall-VS-Normal |
2.06530015312012E-10 |
| Follicular-VS-Other |
7.220200E-01 |
| Follicular-VS-Normal |
3.41210004695114E-09 |
| Other-VS-Normal |
1.392260E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11577413974828E-13 |
| Normal-vs-N1 |
4.95529950406137E-10 |
| N0-vs-N1 |
7.919400E-01 |
|
|
